STROMECTOL (ivermectin) tablets – prescribing information, revised 3/2022 (NDA 050742) (2022)

Government Record · Merck Sharp & Dohme LLC (labeler); U.S. Food and Drug Administration · March 2022

Merck Sharp & Dohme LLC (labeler), 2022-03: The current FDA-approved label for the U.S. brand, limited to intestinal strongyloidiasis and onchocerciasis.

STROMECTOL is indicated for the treatment of intestinal (i.e., nondisseminated) strongyloidiasis due to the nematode parasite Strongyloides stercoralis.

3

Merck Sharp & Dohme LLC (labeler), 2022-03: The current FDA-approved label for the U.S. brand, limited to intestinal strongyloidiasis and onchocerciasis. C6 FDA Stromectol label. Record fields: indications are (1) intestinal strongyloidiasis and (2) onchocerciasis due to Onchocerca volvulus; the label states the onchocerciasis indication rests on 'randomized, double-blind, placebo-controlled and comparative studies conducted in 1427 patients in onchocerciasis-endemic areas of West Africa' with DEC-C as comparator, and that the drug 'has no activity against adult Onchocerca volvulus parasites'. Description section: 'STROMECTOL (Ivermectin) is a semisynthetic, anthelmintic agent for oral administration.' Revised 3/2022. Page number is the PDF page (label page 3 of 11). Also filed as IVB-24, IVA-63 (claims C6, F2). Study type: regulatory record.